Join
Live feed
·
PRReleasevia Quantisnow
Galecto Inc. logo

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

ByQuantisnow·Wall Street's wire, on your screen.
GLTO· Galecto Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GLTO (Galecto Inc.) and more on Quantisnow.